CClinicalTrials.gg
CompletedNCT06962384Updated Jun 3, 2025

Comparing Posterior Release Sclerotomy With Conventional Evisceration Surgery.

An interventional study of Posterior release sclerotomy and Conventional Ball Implantation in Evisceration, Ocular Trauma and Blind Painful Eye, sponsored by Fayoum University Hospital. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Fayoum University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled May 2024, registered Apr 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this interventional study is to compare posterior release sclerotomy in the scleral cup with conventional ball implantation during evisceration, focusing on intraoperative feasibility, postoperative outcomes, and implant stability.

Specific objectives include:

  1. Assessing the rate of implant migration and extrusion.
  2. Evaluating the long-term stability of the implant within the scleral shell.
  3. Investigating the occurrence of complications such as exposure or infection.
  4. Analyzing the functional and anatomical outcomes.
  5. Comparing patient satisfaction and quality of life measures.
Read the detailed description

Evisceration is a widely performed ocular procedure aimed at removing intraocular contents while preserving the scleral shell and extraocular muscles. The primary goal of evisceration is to provide a structurally stable orbital implant, ensuring optimal prosthetic motility and cosmetic appearance. Traditional evisceration with ball implantation often presents complications related to limited space within the scleral cavity, potentially leading to implant extrusion or migration.

A key advancement in evisceration techniques is posterior release sclerotomy within the scleral cup, which aims to expand the intraocular space and facilitate primary ball implantation. By creating a controlled posterior opening, this method is hypothesized to reduce intraoperative resistance to implant insertion, minimize excessive intraocular pressure, and decrease postoperative complications such as extrusion or exposure. However, comparative studies on the effectiveness of posterior release sclerotomy versus conventional ball implantation remain limited.

Conventional evisceration techniques involve creating a scleral incision to accommodate the ball implant, often requiring significant manipulation to fit the prosthesis securely. The resultant tight fit can lead to ischemic changes, delayed healing, and an increased risk of implant extrusion. In contrast, posterior release sclerotomy allows for better distribution of intraocular pressure and improved accommodation of the implant, potentially reducing postoperative complications.

Several studies have highlighted the importance of scleral integrity and orbital volume restoration in optimizing prosthetic movement and overall aesthetic outcomes. Ensuring adequate implant placement without undue pressure on the scleral shell is a crucial factor in preventing long-term complications such as conjunctival dehiscence or implant migration. Posterior release sclerotomy may offer a surgical advantage by providing additional space for implantation, reducing undue pressure, and preserving the scleral integrity.

Despite these theoretical advantages, clinical evidence comparing posterior release sclerotomy with conventional ball implantation remains scarce. Previous retrospective studies suggest that modified techniques may enhance surgical ease and reduce complications.

The present study aims to compare posterior release sclerotomy in the scleral cup with conventional ball implantation during evisceration, focusing on intraoperative feasibility, postoperative outcomes, and implant stability.

This prospective, randomized, controlled trial will be conducted at the Department of Ophthalmic Surgery, Factuality of medicine, Fayum university.

The study will enroll patients requiring evisceration to one of two groups:

  • Posterior Release Sclerotomy Group (PRS Group): Underwent evisceration with posterior release sclerotomy before primary ball implantation.
  • Conventional Ball Implantation Group (CBI Group): Underwent standard evisceration with direct ball implantation without posterior sclerotomy.

    1. History Taking
  • Ocular History: Duration and cause of blindness, previous surgeries/trauma, pain, inflammation, or medication use.
  • Systemic History: Comorbidities (diabetes, hypertension, autoimmune diseases), history of radiation or malignancies.
  • Medication History: Use of anticoagulants or immunosuppressants affecting bleeding or healing.

    1. Clinical Examination
  • Visual Acuity Testing (if applicable)
  • Slit-lamp Examination: Corneal clarity, conjunctival health, intraocular inflammation.
  • Tonometry: Intraocular pressure measurement.
  • Fundus Examination: To rule out intraocular pathology.
  • External Examination: Eyelid position, orbital contour, tenderness, masses. 3. Preoperative Investigations
  • CBC, Coagulation Profile .
  • FBS \& HbA1c.
  • Orbital Ultrasound (if needed) : Assess scleral integrity.
  • CT Orbit (if indicated): For suspected fractures, tumors.

Surgical Procedure All surgeries were performed under general anesthesia by an experienced ophthalmic surgeon. Standard sterile techniques were followed, and appropriate antibiotic prophylaxis was administered preoperatively.

  1. Preoperative Preparation

    • Antibiotic prophylaxis: Intravenous cefazolin (1g) was given 30 minutes before surgery.
    • The surgical site was prepared with povidone-iodine 5%, and a lid speculum was placed.
    • A 360-degree conjunctival peritomy was performed using Westcott scissors, followed by meticulous dissection to expose the scleral shell.
  2. Evisceration Procedure
  3. Group-Specific Implantation Procedures Posterior Release Sclerotomy Group (PRS Group) Conventional Ball Implantation Group (CBI Group)

    • No posterior sclerotomy was performed.
    • The implant was inserted directly into the scleral cup, requiring greater force to accommodate the implant within the available space.
  4. Closure and Conformer Placement

    • The scleral flaps were sutured in a purse-string fashion using non-absorbable 6-0 sutures.
    • The conjunctiva was closed with interrupted 8-0 Vicryl sutures to ensure proper healing.
    • A temporary conformer was placed inside the orbit to maintain the fornices and prevent conjunctival contracture.
    • The surgical site was padded and bandaged to provide adequate protection and minimize postoperative swelling.
  5. Postoperative Care

    • Patients were monitored for early complications (e.g., bleeding, infection).
    • Topical antibiotics and corticosteroids were prescribed postoperatively.
    • Patients were followed up at 1 week, 1 month, and 6 months to assess implant stability, healing, and cosmetic outcomes.

Outcome Measures Primary Outcome

  • Implant extrusion/migration rate within 6 months Secondary Outcomes
  • Surgical ease and intraoperative difficulty score
  • Postoperative pain (Visual Analogue Scale score)
  • Healing time (conjunctival re-epithelialization)
  • Implant stability and motility
  • Cosmetic outcome (patient satisfaction scores, prosthesis motility)

Ethical consideration:

All the individuals included in the study will be informed about the procedures regarding the study and will be informed of their rights to refuse participation or withdraw from the study without having to give reasons. Participants will be guaranteed anonymity and all information provided would be treated with confidentiality. The ethical approval of the faculty of medicine, fayoum university research ethical committee (REC) will be obtained prior to the beginning of the work.

02

Conditions studied

  • Evisceration
  • Ocular Trauma
  • Blind Painful Eye
  • Phthisis Bulbi
  • End Stage Glaucoma

Browse trials for

Keywords

  • Evisceration
  • Ball implantation
  • Posterior release sclerotomy
03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's enrollment of 80 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Fayoum University Hospital is the lead sponsor of 73 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 18 years or older
  • Indication for evisceration due to a non-malignant cause, such as painful blind eye, severe ocular trauma, end-stage glaucoma, or phthisis bulbi
  • Adequate scleral integrity to allow for ball implantation
  • No history of previous intraocular surgery or scleral weakening disorders

Exclusion criteria

Exclusion Criteria:

  • Orbital malignancy or suspected intraocular tumor
  • Active ocular or periocular infection
  • History of radiation therapy to the orbit
  • Severe scleral thinning that contraindicates scleral preservation
  • Presence of autoimmune disease affecting wound healing
  • Psychiatric disorders affecting compliance with postoperative care
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Posterior Release Sclerotomy Group (PRS Group)

    A key advancement in evisceration techniques is posterior release sclerotomy within the scleral cup, which aims to expand the intraocular space and facilitate primary ball implantation. By creating a controlled posterior opening, this method is hypothesized to reduce intraoperative resistance to implant insertion, minimize excessive intraocular pressure, and decrease postoperative complications such as extrusion or exposure

    Procedure: Posterior release sclerotomy

  • Experimental
    Conventional Ball Implantation Group (CBI Group)

    Conventional evisceration techniques involve creating a scleral incision to accommodate the ball implant, often requiring significant manipulation to fit the prosthesis securely. The resultant tight fit can lead to ischemic changes, delayed healing, and an increased risk of implant extrusion.

    Procedure: Conventional Ball Implantation

Interventions

  • ProcedurePosterior release sclerotomy

    * A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents. * The scleral shell was cauterized to eliminate any residual uveal tissue. * Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications. Posterior Release Sclerotomy Group (PRS Group) * A posterior sclerotomy (2-3 mm) was created at the posterior pole of the scleral shell using a crescent blade. * This sclerotomy expanded the intraocular space, reducing intraoperative resistance during implant insertion. * The spherical implant was gently placed within the expanded scleral shell, ensuring minimal stress on the tissue.

  • ProcedureConventional Ball Implantation

    * A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents. * The scleral shell was cauterized to eliminate any residual uveal tissue. * Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications. * No posterior sclerotomy was performed. * The implant was inserted directly into the scleral cup, requiring greater force to accommodate the implant within the available space.

06

What researchers measure

Primary outcomes

  1. • Implant extrusion/migration rate within 6 months

    The primary outcome measure was implant stability, assessed clinically and through imaging at 1, 3, and 6 months postoperatively to review any signs of implant migration or extrusion as well as signs of conjunctival erosion.

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. Patient satisfaction with implant motility

    Assessed through a standardized questionnaire. Measuring patient satisfaction by giving a score from 1-5, where 5 means excellent and 1 means very poor.

    Time frame: From enrollment to the end of the follow up period after 6 months

  2. Postoperative pain

    The Quality of Life Score was determined using a Visual Analog Scale (VAS), which is a straight horizontal line, usually 10 mm. The ends of which are described as the extreme limits of the parameter to be measured oriented from the left (worst) to the right (best).

    Time frame: From enrollment to the end of the follow up period after 6 months

  3. Postoperative complications

    Time frame: From enrollment to the end of the follow up period after 6 months

07

Study locations

1 site
  • Fayoum university hospital
    Fayoum, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06962384
Lead sponsor
Fayoum University Hospital
Responsible party
Khaled Kotb Abdallah (Lecturer of ophthalmology fayoum university, Fayoum University Hospital) — Principal investigator
First posted
May 8, 2025
Start date
May 1, 2024
Primary completion
Apr 28, 2025
Completion
Apr 28, 2025
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion